| Literature DB >> 23139745 |
Hannes VoSSfeldt1, Malte Butzlaff, Katja PrüSSing, Róisín-Ana Ní Chárthaigh, Peter Karsten, Anne Lankes, Sabine Hamm, Mikael Simons, Boris Adryan, Jörg B Schulz, Aaron Voigt.
Abstract
Polyglutamine (polyQ) diseases represent a neuropathologically heterogeneous group of disorders. The common theme of these disorders is an elongated polyQ tract in otherwise unrelated proteins. So far, only symptomatic treatment can be applied to patients suffering from polyQ diseases. Despite extensive research, the molecular mechanisms underlying polyQ-induced toxicity are largely unknown. To gain insight into polyQ pathology, we performed a large-scale RNAi screen in Drosophila to identify modifiers of toxicity induced by expression of truncated Ataxin-3 containing a disease-causing polyQ expansion. We identified various unknown modifiers of polyQ toxicity. Large-scale analysis indicated a dissociation of polyQ aggregation and toxicity.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23139745 PMCID: PMC3489908 DOI: 10.1371/journal.pone.0047452
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240